{"ticker": {"uuid": "3419db25-39d7-4f25-905b-f46def9d55f7", "symbol": "CTOR", "name": "Citius Oncology, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFBrOTFtaVFUOWU3T2FIMW9LV3JUWGRSV05wb1JtTUNIZVo5ZkVvM3pWTzF3d19odGMxdnBfYkFETzFCUVljMlRIY2Z4UG8yem5nb1p0eHhnYUozMzQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:00:01+00:00", "published_display": "11 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Citius Oncology, Inc. \u2013 NASDAQ:CTOR", "summary": "This page displays the enterprise value to EBITDA forward for Citius Oncology, Inc. (NASDAQ: CTOR). It is primarily a financial data point from TradingView, indicating no current trades and providing a basic overview of the company's financial metrics. The article provides no spe", "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:11:24", "published_display": "27 Jun 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Actuals & Estimates (NASDAQ:CTOR)", "summary": "This article provides an overview of Citius Oncology, Inc. (NASDAQ:CTOR) stock performance, analyst estimates, and financial data. It highlights the current stock price, recent declines, future price forecasts from analysts, historical highs and lows, and upcoming earnings report", "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:54", "published_display": "26 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Citius Oncology, Inc. \u2013 NASDAQ:CTOR", "summary": "This article provides a financial overview of Citius Oncology, Inc. (NASDAQ: CTOR), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or preview from a financial data platform like TradingView, indicating that the detailed financial data for this ", "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T17:10:34", "published_display": "26 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Actuals & Estimates (BOATS:CTOR)", "summary": "This article provides an overview of Citius Oncology, Inc. (CTOR) stock performance and financial estimates. It details analyst forecasts, historical price data, upcoming earnings reports, and past financial results including earnings per share, revenue, and net income, noting th", "url": "https://www.tradingview.com/symbols/BOATS-CTOR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:11:24", "published_display": "26 Jun 2026 12:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTOR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Citius Oncology, Inc. (CTOR) stock, including a 1-year price target of $4.00 from one analyst. It details current stock performance, market capitalization, volatility, and historical price data. The piece also covers financial information like", "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:34", "published_display": "26 Jun 2026 07:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Inc (CTOR) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Citius Oncology Inc (CTOR), noting its current valuation score of 7.36 within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.43, which is positioned between its recent high and low, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctor/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-24T09:11:21", "published_display": "24 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Citius Oncology Inc (CTOR) has an earnings forecast score of 8.00, placing it well within the Biotechnology & Medical Research industry. Analysts have set an average price target of $6.00 for the stock, with a consensus of \"Buy\" based on one analyst's rating. The company's expect", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctor/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T04:40:27", "published_display": "18 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Citius Oncology Inc's (CTOR) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also displays current stock price informatio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctor/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:27", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Citius Oncology Inc (CTOR), including business segments, regional revenue, and profit contribution. However, the article explicitly states that relevant data have not been disclosed by the company yet, makin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctor/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:27", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides access to Citius Oncology, Inc.'s financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. It details key corporate events, earnings reports, and operational updates from 2024 to early 2026, highlighting the launch and impact of their product", "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/documents/", "source_name": "TradingView", "published_at": "2026-06-04T11:10:49", "published_display": "04 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data", "summary": "Citius Oncology (CTOR) has registered 6.8 million warrant shares, leading to approximately $6.1 million in net proceeds for the company. Concurrently, the company highlighted positive Phase 1 clinical data for LYMPHIR in combination with pembrolizumab, showing durable responses a", "url": "https://www.stocktitan.net/sec-filings/CTOR/424b3-citius-oncology-inc-prospectus-filed-pursuant-to-rule-424-b-3-a6ac03523909.html", "source_name": "Stock Titan", "published_at": "2026-06-03T01:10:42", "published_display": "03 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results", "summary": "Citius Oncology (NASDAQ: CTOR) announced encouraging early Phase 1 data for its drug LYMPHIR in combination with pembrolizumab in heavily pre-treated patients with recurrent or refractory gynecologic cancers. The study showed a 48% clinical benefit rate among efficacy-evaluable p", "url": "https://www.stocktitan.net/sec-filings/CTOR/8-k-citius-oncology-inc-reports-material-event-f753f9b247a2.html", "source_name": "Stock Titan", "published_at": "2026-06-02T00:39:17", "published_display": "02 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology presents study data on LYMPHIR combination", "summary": "Citius Oncology presented Phase 1 clinical data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies at the American Society of Clinical Oncology Annual Meeting. The study showed a 24% overall response rate with five partial responses", "url": "https://www.investing.com/news/company-news/citius-oncology-presents-study-data-on-lymphir-combination-93CH-4718825", "source_name": "Investing.com", "published_at": "2026-06-01T22:11:01", "published_display": "01 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology presents study data on LYMPHIR combination By Investing.com", "summary": "Citius Oncology presented positive Phase 1 clinical data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies at the American Society of Clinical Oncology Annual Meeting. The study showed a 24% overall response rate and a 33% objectiv", "url": "https://ng.investing.com/news/stock-market-news/citius-oncology-presents-study-data-on-lymphir-combination-93CH-2537162", "source_name": "Investing.com Nigeria", "published_at": "2026-06-01T11:40:40", "published_display": "01 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR\u00ae (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies", "summary": "Citius Oncology announced encouraging Phase 1 clinical data for LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab for recurrent or refractory gynecologic malignancies, presented at the ASCO Annual Meeting. The study demonstrated durable responses and manageable", "url": "https://www.prnewswire.com/news-releases/citius-oncology-highlights-phase-1-data-in-an-investigator-initiated-study-of-lymphir-denileukin-diftitox-cxdl-in-combination-with-pembrolizumab-in-recurrent-or-refractory-gynecologic-malignancies-302786610.html", "source_name": "PR Newswire", "published_at": "2026-06-01T07:00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTOR - Citius Oncology Inc Stock Price and Quote", "summary": "This article provides detailed stock information for Citius Oncology Inc. (CTOR), including its current stock price, financial metrics, analyst ratings, and recent news announcements. Key highlights include the company's financial performance, insider and institutional ownership,", "url": "https://finviz.com/stock?t=CTOR", "source_name": "Finviz", "published_at": "2026-05-29T21:41:50", "published_display": "29 May 2026 21:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (NASDAQ: CTOR) clears potential $25M loan conversions and large warrants", "summary": "Citius Oncology (NASDAQ: CTOR) has informed stockholders that a majority holder approved, via written consent, the potential issuance of common stock related to a Loan and Security Agreement and several warrant transactions. These actions, which include a $25.0 million loan facil", "url": "https://www.stocktitan.net/sec-filings/CTOR/def-14c-citius-oncology-inc-definitive-information-statement-ea074f828e74.html", "source_name": "Stock Titan", "published_at": "2026-05-29T21:10:49", "published_display": "29 May 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (Nasdaq: CTOR) registers 32.9M shares tied to warrants and loan conversion", "summary": "Citius Oncology (Nasdaq: CTOR) has registered 32.9 million shares of common stock for resale by selling stockholders, stemming from warrant exercises and loan conversions. The company will not receive proceeds from these resales, but could gain up to $26.5 million if all warrants", "url": "https://www.stocktitan.net/sec-filings/CTOR/s-3-citius-oncology-inc-shelf-registration-statement-0fc6ac71469d.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:10:49", "published_display": "29 May 2026 20:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Citius Oncology, Inc. \u2013 NASDAQ:CTOR", "summary": "This article provides details on the number of shareholders for Citius Oncology, Inc. (NASDAQ: CTOR). It indicates that the data is presented for a specific period, showing its value and percentage change. The content also includes various disclaimers regarding data sources.", "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-26T17:10:14", "published_display": "26 May 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Announces Presentation of LYMPHIR\u00ae Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/citius-oncology-announces-presentation-lymphir-120000815.html", "source_name": "PR Newswire", "published_at": "2026-05-26T12:00:00+00:00", "published_display": "26 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/citius-pharmaceuticals-inc-ctxr-among-114930943.html", "source_name": "Insider Monkey", "published_at": "2026-05-24T11:49:30+00:00", "published_display": "24 May 2026 11:49", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (CTOR) registers 6.82M warrant shares; May 2026 financing steps", "summary": "Citius Oncology (CTOR) registered 6.82 million shares underlying warrants and confirmed 272,727 placement agent warrants remain outstanding as of a May 15, 2026 prospectus supplement. The company received approximately $6.1 million in net proceeds from warrant exercises at a redu", "url": "https://www.stocktitan.net/sec-filings/CTOR/424b3-citius-oncology-inc-prospectus-filed-pursuant-to-rule-424-b-3-6fafa5f05e6a.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:18", "published_display": "22 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (NASDAQ: CTOR) majority approves warrant and conversion issuances", "summary": "Citius Oncology (NASDAQ: CTOR) announced that a majority of its shareholders approved the issuance of common stock related to lender warrants, May 2026 warrants, amended December 2025 warrants, and a lender conversion option. These approvals are linked to a $25.0 million loan pac", "url": "https://www.stocktitan.net/sec-filings/CTOR/pre-14c-citius-oncology-inc-preliminary-information-statement-517755e01cb5.html", "source_name": "Stock Titan", "published_at": "2026-05-19T20:09:53", "published_display": "19 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LYMPHIR cancer drug at 83% of target accounts, coverage near 100%", "summary": "Citius Oncology reported Q2 2026 financial results, including $1.7 million in quarterly LYMPHIR revenue and $5.6 million for the first half of fiscal 2026, with an 80% gross margin. The company achieved broad market access for LYMPHIR, with 83% of target accounts having it on for", "url": "https://www.stocktitan.net/news/CTOR/citius-oncology-inc-reports-fiscal-second-quarter-2026-financial-j1v8tzq3nquf.html", "source_name": "Stock Titan", "published_at": "2026-05-19T19:09:03", "published_display": "19 May 2026 19:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Armistice Capital (CTOR) files 9.99% ownership disclosure", "summary": "Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9,299,917 shares, representing 9.99% of Citius Oncology, Inc. (CTOR) common stock as of March 31, 2026. This ownership is held through Armistice Capital Master Fund Ltd., with Armistice Capital and Mr.", "url": "https://www.stocktitan.net/sec-filings/CTOR/schedule-13g-a-citius-oncology-inc-amended-passive-investment-disclos-8ce19bac9dab.html", "source_name": "Stock Titan", "published_at": "2026-05-16T03:09:03", "published_display": "16 May 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/citius-pharmaceuticals-inc-reports-fiscal-203000639.html", "source_name": "PR Newswire", "published_at": "2026-05-15T20:30:00+00:00", "published_display": "15 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CITIUS ONCOLOGY, INC. 3Q 2026: Revenue $1.67M, EPS $(0.27) \u2014 10-Q Summary", "summary": "CITIUS ONCOLOGY, INC. (CTOR) reported first commercial revenue of $1.67 million for the third quarter ended March 31, 2026, marking a significant milestone from zero revenue in the prior year. Despite this, the company posted a net loss of $(26.61M) or diluted loss per share of $", "url": "https://www.tradingview.com/news/tradingview:954805c1b2c27:0-citius-oncology-inc-3q-2026-revenue-1-67m-eps-0-27-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-15T20:39:32", "published_display": "15 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology reports $5.6M H1 revenue, $26.6M Q2 net loss; secures up to $36.5M financing", "summary": "Citius Oncology reported $5.6 million in product revenue for the first half of FY2026, driven by the December 2025 launch of LYMPHIR, and a Q2 net loss of $26.6 million. The company secured up to $36.5 million in post-quarter-end debt and equity financing to support commercial op", "url": "https://www.tradingview.com/news/tradingview:6d2c36bc140f5:0-citius-oncology-reports-5-6m-h1-revenue-26-6m-q2-net-loss-secures-up-to-36-5m-financing/", "source_name": "TradingView", "published_at": "2026-05-15T20:39:32", "published_display": "15 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQdDVVYXRySHpab0tWbjYxN3lMblY4dUEwMUNrNV9xLTYyYnVaTXMySXZURnNIeEk3eDA2bEhleGg5UUpndzd1TEFtaEp2bm91THdsMmdSX2ZFcU5ITFc0V3lyaV8xcVVEeWtDN1UtMHYtYjMwQk4yZmdHMjFkQ0VYVzBOZDZoZ0hfNzBnQjJpWHFiTExCOVk5RGZCNGM4bDJ2VEVyOTZoM0E3NnRBd0lZekcxdGhrenh2azNRSTV6MzNGU084ZlVxTjh2TWdJNHotdGxrUFk1ZElVS29GZFhXUWlfRkFULUxvUHZqelVR?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (Nasdaq: CTOR) lines up $36.5M to fund LYMPHIR", "summary": "Citius Oncology (Nasdaq: CTOR) has secured up to $36.5 million in financing to support the commercialization of its oncology therapy, LYMPHIR. This funding includes a senior secured term loan facility of up to $25 million from Avenue Capital Group and approximately $11.5 million ", "url": "https://www.stocktitan.net/sec-filings/CTOR/8-k-citius-oncology-inc-reports-material-event-ec1934a50679.html", "source_name": "Stock Titan", "published_at": "2026-05-08T02:09:43", "published_display": "08 May 2026 02:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (NASDAQ: CTOR) registers 6.82M warrant shares, updates LYMPHIR trials and launch", "summary": "Citius Oncology registered 6.82 million warrant shares and provided updates on its LYMPHIR product. The company shared positive Phase 1 trial data for LYMPHIR in combination with CAR-T therapy for DLBCL and with pembrolizumab for gynecologic cancers, demonstrating promising respo", "url": "https://www.stocktitan.net/sec-filings/CTOR/424b3-citius-oncology-inc-prospectus-filed-pursuant-to-rule-424-b-3-f557a3d6da1a.html", "source_name": "Stock Titan", "published_at": "2026-05-07T14:08:58", "published_display": "07 May 2026 14:08", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Secures Up to $25M Term Loan and $11.5M Warrant Proceeds to Fund Commercialization", "summary": "Citius Oncology has secured significant financing to bolster its liquidity for the commercialization of LYMPHIR and other corporate needs. The company obtained a secured term loan facility of up to $25 million from Avenue funds, with an initial draw of $10 million, and generated ", "url": "https://www.tradingview.com/news/tradingview:dff17978a3186:0-citius-oncology-secures-up-to-25m-term-loan-and-11-5m-warrant-proceeds-to-fund-commercialization/", "source_name": "TradingView", "published_at": "2026-05-07T11:40:23", "published_display": "07 May 2026 11:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius raises $36.5m for Lymphir commercialisation", "summary": "", "url": "https://finance.yahoo.com/m/c8fafcbb-c320-33b2-a4b0-de65d15346ff/citius-raises-%2436.5m-for.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-05-06T13:04:52+00:00", "published_display": "06 May 2026 13:04", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules", "summary": "Citius Oncology announced the closing of an $18 million concurrent registered direct offering and private placement. The pricing for these offerings was at-the-market under Nasdaq rules. This financial move provides Citius Oncology with additional capital.", "url": "https://quantisnow.com/insight/citius-oncology-announces-closing-of-18-million-concurrent-registered-direct-6310775", "source_name": "Quantisnow", "published_at": "2026-05-06T11:09:13", "published_display": "06 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR\u00ae Commercialization", "summary": "Citius Oncology, Inc. has secured up to $36.5 million in debt and equity capital to accelerate the commercialization of its FDA-approved drug, LYMPHIR\u00ae, for cutaneous T-cell lymphoma (CTCL). The financing includes a senior secured term loan facility of up to $25 million from Aven", "url": "https://www.prnewswire.com/news-releases/citius-oncology-inc-secures-up-to-36-5-million-in-debt-and-equity-capital-to-accelerate-lymphir-commercialization-302763264.html", "source_name": "PR Newswire", "published_at": "2026-05-05T23:39:33", "published_display": "05 May 2026 23:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius gets $36.5M to back LYMPHIR, its CTCL therapy launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNUDNzT1Q5LXpKdEhybG1qQkZZeXA5dmpmclRsTkpwM1VSTG1yRXo3OGI2dVVPTWZWOUlIYmdhZDdBWElRZThiN2ljdW1NWUllQmJnVWk4UTJ0WlgzTndYcmp2WURPekNRaExtNHA1MGVUOF9HQk1RUTZfeGFpLXZTa3BnTTZzS1J6YnlqTmVjbXNmR3V4V3B3ZlJHM21BenN2MUY0blhTRTdDRUd5OUNmVWdvQlRyNnA5ZlZXeQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Ships First International Order of LYMPHIR\u2122 to Europe", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQUlIwM0t2WXdRZzMzTzJtbWZtcVd1ekp5dThaY0hqbHhqdi1ETi05Q0ViUE5SbUZLSE9zckpPZmNaZ1VHT2FUc25qb0NUUHp5WE1hOVBSLUNja3VNdU9mMHNtZmVmZGFudzRKMVFITHpqQkhrVW1ReERYcFNVc2xqMlA2aFZPYmU2Rnl6T3dFQ055aTZubG9zTW55QWw1TEV5YzR0N2x2eDVsTHh3RWo3TURTSWEwWjROM2pfNVZKX2wzdw?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTOR Stock Price and Chart \u2014 NASDAQ:CTOR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBfb19pMzljR0tOTlRqWkNrSHpNRUUzS2RLdlFWSEVLeEFkQW1FcUlZZl8yV1FBVUtreW9icUw3ZC1IcEVhNVhWOFdtdk1JUUdnRUY2UG5EWGRzbXNJ?oc=5", "source_name": "TradingView", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR\u2122", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxONDgxU3ZwZTE0VkQtSEQxdFhPTERjZGVhcldVVzl1ZG1yVWhWRUNQT3J5S3NFUmc5SWhlcmtBdkxyeEVla3diaFI0bl9Lcm5QTHhLYThwb0FoRlFCRllxOHdyYi0wZ1o2LUlLaXhBMVZ3ZWczUkRJeFUwcEk0T3FYOG5laWZtMEp3MlozOXprV2t6YzE1Um82cGszNEtlRDFKd0djdmFZQ1ZIZzMzbjlvMXFvWjFHRkw5RFFYRjd2dDV3ZGUyMGxTcFlnbl80QTFHWUFJVFVXSW5mRHVjOUNDaA?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNaG56OFpUWENIb0xBSXFPNDlBaThXQkNYMDRhM0hvSnAtX2R4akhWbDFpbzVra2I3dGtpTldGZGgwN1pua3ZiWXhlY20tUURYdXpQUTN2UWFJckh3SVB5WjRNNXdXM2VPcy1aVlB1blBFZ0o2cEIta1ZDWWlNWHA3RjFYbmREX2JRQXVFamtiR2xYUUdQZjNxUnBNSkVHendEVkx0ckhJRURlM01nQXI5cThNMHZ1Zm9MSEpUT3hzU1A5S09jS1hQeUdEUW9xTzJkTlNQSmlSTlBDczJuRDF4Rw?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAJBVV95cUxPcnFyT1VfWTNhamdiWWktR2lKMWJWOXVucmJSaGMzUFp3ZzZtWDhFaTBvRWczSWY5QWxSX2dSQWJwSXVKdm04SkNVbnlmZDZUdkhEZjNuNl9VNVdyRHU1b01lLW9XWG4tVXpCejNybkRhaHZTc2JHVk1nUjFreFdzdDRhRFNZcFFCZFB6UXI5dFV5RFZfVDhjR2tNSWdwengzMVd1T0NCdXcyMFFKcUVNVk1RclM2RXNRdnpQQ0RsUlY5bWZyREhKQkc5cWJLYWV1MXpEV3Aza1BSaGRLWFNpT3BMaDBuY3lnRGoyR0cxTkluNWJGSElibW01S3Jvbjl2WENrY0plVTBvVlZrbE1rWnZ0UHk0X21kamJvRQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Expands LYMPHIR\u2122 Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxNLTFKQ0JxUUVVNzZJTnVmMTk0RGhCa3hBQ2hwNFlVS0VDUnV2Y0JwU09mOEpwWFFsNW13NFZiUnQ1clk3bHNCTWZJZXJZbV9tSkV4UUc4NzNXR2o1dU5WWVozWGFVM2tyOHAtWERHY21XdmlfLU13TDZabGRpMU1OUVQyZDdHUENidFJhQlFsSHhsRXF6anNILUxPNVhmNTM0MDI0QUpOVFlMNFRFVlFma0RZTjg4RTJ1LU9UaTcwakFVR3F3ZXBScmI2dmdVSWc1TUd2OFA3enkzX3cwSVhWQ1dBd0RFUDZsQkM0dW9zNlFGNkdrdmFwSDBsWVE3eDRwQXJXSm1odw?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQNEhzQm5LcVZJUDNfTmgzUXBrbVktcWUzRXk0ZERKTkNuM0Q0TE01d0JxYzIxR2NvVW1Fd2NlV1RzdFRFWFdXeEZMN24zLVRveDVjZjFWOFlVNWZwc08zZTJKUk5hQW9tMjhTWnJTemtGdllGSjk0eHI5RXNtWEdycy1TdEdyNF8xNGlldmNCZW4xZy04bXhSZFNqeVVIWVVmQUt0VUNhaUFmMlN0UmtkVnFNNlJYbmRoOUgtNW1DY0tjNUJsaUZmQ3Bobnpnajc4bGJxc3FxZTV3VGtpenJjQ2RWUFVEYVNFazV3blUtQnJLLVB6Nk1F?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-10T07:00:00+00:00", "published_display": "10 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (CTOR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5RdGVXTmxSM003X05Tanl5MUJtdjE1dGZuTHpQTkVfQ3BJRmZLVy1uMERYdDdUUjVMS1QzRTEtYkJ0WkxneFlCMGhCVndfMXhVZ19n?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:37:19+00:00", "published_display": "25 Apr 2025 02:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBqUDBleUFtOUFlVlRXX3I4MU53SVdzd2tQaFpONW8zekdaWGxLSHdsamRoUkZmMXZqYWhaY2dBRHFjZ2ZEcW5hMnI1YTJXYm5zT01B?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T22:54:07+00:00", "published_display": "24 Apr 2025 22:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (CTOR) Stock Price, News & Analysis $CTOR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBmR01DOXBKM3Z3djZNVUt5NnVrNURnd1BEQ3lOUjVPM0VzVWlSeDg4TjFJc2g0bjNOM2FLcThyVmJ6TUFpRW1kQmJJVnBNdUVGY1YtTUc2bklWQQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-08-14T20:37:36+00:00", "published_display": "14 Aug 2024 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAJBVV95cUxPVjFZanlQenJ0ZXJvTU1PRGhxVG1TN0V5UmJ2QjVxQ1ZDM1NtdFVsWFVSb2o4a1hBZUphM0o5eU1Kdnh0SWRCTmVVcWxldmtGMHhHa0tENWV0d1Y3eVZZMTQ2Mk5pSEM3T1I4aVpaMjRjYjVSVjdhUlltVnEwNGpLY1pLVWFxZXVlTGJoZlRhMjlSNGhUeS1tVnEyeG5ENXJ6R3d3azdJaDFfa2VpbUkzbXUtSGZLUm1aV1ExVllNYUZkUHZQVENUSnhSalRId0xteTQ2U3gtR1I5VjR1LWZWTkc0WThBaERyTnJwS21zaXhlYXM2clkxRmV0cjdoaXkyX1VLOUdPVzJydzdnTEVRVU9fMXp6cE81YVRIQmNSbnhjSkVlMFdtRFJtUVlMbG1BdlY0c0JnOFQ?oc=5", "source_name": "PR Newswire", "published_at": "2023-10-24T07:00:00+00:00", "published_display": "24 Oct 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals (CTXR) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBzUFR4clRxVFVCLWx5SWZWNnRTT2lCUndEZ3JKeWRBd2cwbnFQMVlsZlFJUndnOFdrMlQtZzlBNWdtWVBQVDRmRWM3cUNwQQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-08-03T02:51:15+00:00", "published_display": "03 Aug 2020 02:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFBrOTFtaVFUOWU3T2FIMW9LV3JUWGRSV05wb1JtTUNIZVo5ZkVvM3pWTzF3d19odGMxdnBfYkFETzFCUVljMlRIY2Z4UG8yem5nb1p0eHhnYUozMzQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:00:01+00:00", "published_display": "11 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Citius Oncology, Inc. \u2013 NASDAQ:CTOR", "summary": "This page displays the enterprise value to EBITDA forward for Citius Oncology, Inc. (NASDAQ: CTOR). It is primarily a financial data point from TradingView, indicating no current trades and providing a basic overview of the company's financial metrics. The article provides no spe", "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:11:24", "published_display": "27 Jun 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Actuals & Estimates (NASDAQ:CTOR)", "summary": "This article provides an overview of Citius Oncology, Inc. (NASDAQ:CTOR) stock performance, analyst estimates, and financial data. It highlights the current stock price, recent declines, future price forecasts from analysts, historical highs and lows, and upcoming earnings report", "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:54", "published_display": "26 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Citius Oncology, Inc. \u2013 NASDAQ:CTOR", "summary": "This article provides a financial overview of Citius Oncology, Inc. (NASDAQ: CTOR), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or preview from a financial data platform like TradingView, indicating that the detailed financial data for this ", "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T17:10:34", "published_display": "26 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Actuals & Estimates (BOATS:CTOR)", "summary": "This article provides an overview of Citius Oncology, Inc. (CTOR) stock performance and financial estimates. It details analyst forecasts, historical price data, upcoming earnings reports, and past financial results including earnings per share, revenue, and net income, noting th", "url": "https://www.tradingview.com/symbols/BOATS-CTOR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:11:24", "published_display": "26 Jun 2026 12:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTOR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Citius Oncology, Inc. (CTOR) stock, including a 1-year price target of $4.00 from one analyst. It details current stock performance, market capitalization, volatility, and historical price data. The piece also covers financial information like", "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:34", "published_display": "26 Jun 2026 07:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Inc (CTOR) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Citius Oncology Inc (CTOR), noting its current valuation score of 7.36 within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.43, which is positioned between its recent high and low, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctor/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-24T09:11:21", "published_display": "24 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Citius Oncology Inc (CTOR) has an earnings forecast score of 8.00, placing it well within the Biotechnology & Medical Research industry. Analysts have set an average price target of $6.00 for the stock, with a consensus of \"Buy\" based on one analyst's rating. The company's expect", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctor/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T04:40:27", "published_display": "18 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Citius Oncology Inc's (CTOR) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also displays current stock price informatio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctor/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:27", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Citius Oncology Inc (CTOR), including business segments, regional revenue, and profit contribution. However, the article explicitly states that relevant data have not been disclosed by the company yet, makin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ctor/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:27", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides access to Citius Oncology, Inc.'s financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. It details key corporate events, earnings reports, and operational updates from 2024 to early 2026, highlighting the launch and impact of their product", "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/documents/", "source_name": "TradingView", "published_at": "2026-06-04T11:10:49", "published_display": "04 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data", "summary": "Citius Oncology (CTOR) has registered 6.8 million warrant shares, leading to approximately $6.1 million in net proceeds for the company. Concurrently, the company highlighted positive Phase 1 clinical data for LYMPHIR in combination with pembrolizumab, showing durable responses a", "url": "https://www.stocktitan.net/sec-filings/CTOR/424b3-citius-oncology-inc-prospectus-filed-pursuant-to-rule-424-b-3-a6ac03523909.html", "source_name": "Stock Titan", "published_at": "2026-06-03T01:10:42", "published_display": "03 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results", "summary": "Citius Oncology (NASDAQ: CTOR) announced encouraging early Phase 1 data for its drug LYMPHIR in combination with pembrolizumab in heavily pre-treated patients with recurrent or refractory gynecologic cancers. The study showed a 48% clinical benefit rate among efficacy-evaluable p", "url": "https://www.stocktitan.net/sec-filings/CTOR/8-k-citius-oncology-inc-reports-material-event-f753f9b247a2.html", "source_name": "Stock Titan", "published_at": "2026-06-02T00:39:17", "published_display": "02 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology presents study data on LYMPHIR combination", "summary": "Citius Oncology presented Phase 1 clinical data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies at the American Society of Clinical Oncology Annual Meeting. The study showed a 24% overall response rate with five partial responses", "url": "https://www.investing.com/news/company-news/citius-oncology-presents-study-data-on-lymphir-combination-93CH-4718825", "source_name": "Investing.com", "published_at": "2026-06-01T22:11:01", "published_display": "01 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology presents study data on LYMPHIR combination By Investing.com", "summary": "Citius Oncology presented positive Phase 1 clinical data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies at the American Society of Clinical Oncology Annual Meeting. The study showed a 24% overall response rate and a 33% objectiv", "url": "https://ng.investing.com/news/stock-market-news/citius-oncology-presents-study-data-on-lymphir-combination-93CH-2537162", "source_name": "Investing.com Nigeria", "published_at": "2026-06-01T11:40:40", "published_display": "01 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR\u00ae (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies", "summary": "Citius Oncology announced encouraging Phase 1 clinical data for LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab for recurrent or refractory gynecologic malignancies, presented at the ASCO Annual Meeting. The study demonstrated durable responses and manageable", "url": "https://www.prnewswire.com/news-releases/citius-oncology-highlights-phase-1-data-in-an-investigator-initiated-study-of-lymphir-denileukin-diftitox-cxdl-in-combination-with-pembrolizumab-in-recurrent-or-refractory-gynecologic-malignancies-302786610.html", "source_name": "PR Newswire", "published_at": "2026-06-01T07:00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTOR - Citius Oncology Inc Stock Price and Quote", "summary": "This article provides detailed stock information for Citius Oncology Inc. (CTOR), including its current stock price, financial metrics, analyst ratings, and recent news announcements. Key highlights include the company's financial performance, insider and institutional ownership,", "url": "https://finviz.com/stock?t=CTOR", "source_name": "Finviz", "published_at": "2026-05-29T21:41:50", "published_display": "29 May 2026 21:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (NASDAQ: CTOR) clears potential $25M loan conversions and large warrants", "summary": "Citius Oncology (NASDAQ: CTOR) has informed stockholders that a majority holder approved, via written consent, the potential issuance of common stock related to a Loan and Security Agreement and several warrant transactions. These actions, which include a $25.0 million loan facil", "url": "https://www.stocktitan.net/sec-filings/CTOR/def-14c-citius-oncology-inc-definitive-information-statement-ea074f828e74.html", "source_name": "Stock Titan", "published_at": "2026-05-29T21:10:49", "published_display": "29 May 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (Nasdaq: CTOR) registers 32.9M shares tied to warrants and loan conversion", "summary": "Citius Oncology (Nasdaq: CTOR) has registered 32.9 million shares of common stock for resale by selling stockholders, stemming from warrant exercises and loan conversions. The company will not receive proceeds from these resales, but could gain up to $26.5 million if all warrants", "url": "https://www.stocktitan.net/sec-filings/CTOR/s-3-citius-oncology-inc-shelf-registration-statement-0fc6ac71469d.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:10:49", "published_display": "29 May 2026 20:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Citius Oncology, Inc. \u2013 NASDAQ:CTOR", "summary": "This article provides details on the number of shareholders for Citius Oncology, Inc. (NASDAQ: CTOR). It indicates that the data is presented for a specific period, showing its value and percentage change. The content also includes various disclaimers regarding data sources.", "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-26T17:10:14", "published_display": "26 May 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Announces Presentation of LYMPHIR\u00ae Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/citius-oncology-announces-presentation-lymphir-120000815.html", "source_name": "PR Newswire", "published_at": "2026-05-26T12:00:00+00:00", "published_display": "26 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/citius-pharmaceuticals-inc-ctxr-among-114930943.html", "source_name": "Insider Monkey", "published_at": "2026-05-24T11:49:30+00:00", "published_display": "24 May 2026 11:49", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (CTOR) registers 6.82M warrant shares; May 2026 financing steps", "summary": "Citius Oncology (CTOR) registered 6.82 million shares underlying warrants and confirmed 272,727 placement agent warrants remain outstanding as of a May 15, 2026 prospectus supplement. The company received approximately $6.1 million in net proceeds from warrant exercises at a redu", "url": "https://www.stocktitan.net/sec-filings/CTOR/424b3-citius-oncology-inc-prospectus-filed-pursuant-to-rule-424-b-3-6fafa5f05e6a.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:18", "published_display": "22 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (NASDAQ: CTOR) majority approves warrant and conversion issuances", "summary": "Citius Oncology (NASDAQ: CTOR) announced that a majority of its shareholders approved the issuance of common stock related to lender warrants, May 2026 warrants, amended December 2025 warrants, and a lender conversion option. These approvals are linked to a $25.0 million loan pac", "url": "https://www.stocktitan.net/sec-filings/CTOR/pre-14c-citius-oncology-inc-preliminary-information-statement-517755e01cb5.html", "source_name": "Stock Titan", "published_at": "2026-05-19T20:09:53", "published_display": "19 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LYMPHIR cancer drug at 83% of target accounts, coverage near 100%", "summary": "Citius Oncology reported Q2 2026 financial results, including $1.7 million in quarterly LYMPHIR revenue and $5.6 million for the first half of fiscal 2026, with an 80% gross margin. The company achieved broad market access for LYMPHIR, with 83% of target accounts having it on for", "url": "https://www.stocktitan.net/news/CTOR/citius-oncology-inc-reports-fiscal-second-quarter-2026-financial-j1v8tzq3nquf.html", "source_name": "Stock Titan", "published_at": "2026-05-19T19:09:03", "published_display": "19 May 2026 19:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Armistice Capital (CTOR) files 9.99% ownership disclosure", "summary": "Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9,299,917 shares, representing 9.99% of Citius Oncology, Inc. (CTOR) common stock as of March 31, 2026. This ownership is held through Armistice Capital Master Fund Ltd., with Armistice Capital and Mr.", "url": "https://www.stocktitan.net/sec-filings/CTOR/schedule-13g-a-citius-oncology-inc-amended-passive-investment-disclos-8ce19bac9dab.html", "source_name": "Stock Titan", "published_at": "2026-05-16T03:09:03", "published_display": "16 May 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/citius-pharmaceuticals-inc-reports-fiscal-203000639.html", "source_name": "PR Newswire", "published_at": "2026-05-15T20:30:00+00:00", "published_display": "15 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CITIUS ONCOLOGY, INC. 3Q 2026: Revenue $1.67M, EPS $(0.27) \u2014 10-Q Summary", "summary": "CITIUS ONCOLOGY, INC. (CTOR) reported first commercial revenue of $1.67 million for the third quarter ended March 31, 2026, marking a significant milestone from zero revenue in the prior year. Despite this, the company posted a net loss of $(26.61M) or diluted loss per share of $", "url": "https://www.tradingview.com/news/tradingview:954805c1b2c27:0-citius-oncology-inc-3q-2026-revenue-1-67m-eps-0-27-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-15T20:39:32", "published_display": "15 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology reports $5.6M H1 revenue, $26.6M Q2 net loss; secures up to $36.5M financing", "summary": "Citius Oncology reported $5.6 million in product revenue for the first half of FY2026, driven by the December 2025 launch of LYMPHIR, and a Q2 net loss of $26.6 million. The company secured up to $36.5 million in post-quarter-end debt and equity financing to support commercial op", "url": "https://www.tradingview.com/news/tradingview:6d2c36bc140f5:0-citius-oncology-reports-5-6m-h1-revenue-26-6m-q2-net-loss-secures-up-to-36-5m-financing/", "source_name": "TradingView", "published_at": "2026-05-15T20:39:32", "published_display": "15 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQdDVVYXRySHpab0tWbjYxN3lMblY4dUEwMUNrNV9xLTYyYnVaTXMySXZURnNIeEk3eDA2bEhleGg5UUpndzd1TEFtaEp2bm91THdsMmdSX2ZFcU5ITFc0V3lyaV8xcVVEeWtDN1UtMHYtYjMwQk4yZmdHMjFkQ0VYVzBOZDZoZ0hfNzBnQjJpWHFiTExCOVk5RGZCNGM4bDJ2VEVyOTZoM0E3NnRBd0lZekcxdGhrenh2azNRSTV6MzNGU084ZlVxTjh2TWdJNHotdGxrUFk1ZElVS29GZFhXUWlfRkFULUxvUHZqelVR?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (Nasdaq: CTOR) lines up $36.5M to fund LYMPHIR", "summary": "Citius Oncology (Nasdaq: CTOR) has secured up to $36.5 million in financing to support the commercialization of its oncology therapy, LYMPHIR. This funding includes a senior secured term loan facility of up to $25 million from Avenue Capital Group and approximately $11.5 million ", "url": "https://www.stocktitan.net/sec-filings/CTOR/8-k-citius-oncology-inc-reports-material-event-ec1934a50679.html", "source_name": "Stock Titan", "published_at": "2026-05-08T02:09:43", "published_display": "08 May 2026 02:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (NASDAQ: CTOR) registers 6.82M warrant shares, updates LYMPHIR trials and launch", "summary": "Citius Oncology registered 6.82 million warrant shares and provided updates on its LYMPHIR product. The company shared positive Phase 1 trial data for LYMPHIR in combination with CAR-T therapy for DLBCL and with pembrolizumab for gynecologic cancers, demonstrating promising respo", "url": "https://www.stocktitan.net/sec-filings/CTOR/424b3-citius-oncology-inc-prospectus-filed-pursuant-to-rule-424-b-3-f557a3d6da1a.html", "source_name": "Stock Titan", "published_at": "2026-05-07T14:08:58", "published_display": "07 May 2026 14:08", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Secures Up to $25M Term Loan and $11.5M Warrant Proceeds to Fund Commercialization", "summary": "Citius Oncology has secured significant financing to bolster its liquidity for the commercialization of LYMPHIR and other corporate needs. The company obtained a secured term loan facility of up to $25 million from Avenue funds, with an initial draw of $10 million, and generated ", "url": "https://www.tradingview.com/news/tradingview:dff17978a3186:0-citius-oncology-secures-up-to-25m-term-loan-and-11-5m-warrant-proceeds-to-fund-commercialization/", "source_name": "TradingView", "published_at": "2026-05-07T11:40:23", "published_display": "07 May 2026 11:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius raises $36.5m for Lymphir commercialisation", "summary": "", "url": "https://finance.yahoo.com/m/c8fafcbb-c320-33b2-a4b0-de65d15346ff/citius-raises-%2436.5m-for.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-05-06T13:04:52+00:00", "published_display": "06 May 2026 13:04", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules", "summary": "Citius Oncology announced the closing of an $18 million concurrent registered direct offering and private placement. The pricing for these offerings was at-the-market under Nasdaq rules. This financial move provides Citius Oncology with additional capital.", "url": "https://quantisnow.com/insight/citius-oncology-announces-closing-of-18-million-concurrent-registered-direct-6310775", "source_name": "Quantisnow", "published_at": "2026-05-06T11:09:13", "published_display": "06 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR\u00ae Commercialization", "summary": "Citius Oncology, Inc. has secured up to $36.5 million in debt and equity capital to accelerate the commercialization of its FDA-approved drug, LYMPHIR\u00ae, for cutaneous T-cell lymphoma (CTCL). The financing includes a senior secured term loan facility of up to $25 million from Aven", "url": "https://www.prnewswire.com/news-releases/citius-oncology-inc-secures-up-to-36-5-million-in-debt-and-equity-capital-to-accelerate-lymphir-commercialization-302763264.html", "source_name": "PR Newswire", "published_at": "2026-05-05T23:39:33", "published_display": "05 May 2026 23:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius gets $36.5M to back LYMPHIR, its CTCL therapy launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNUDNzT1Q5LXpKdEhybG1qQkZZeXA5dmpmclRsTkpwM1VSTG1yRXo3OGI2dVVPTWZWOUlIYmdhZDdBWElRZThiN2ljdW1NWUllQmJnVWk4UTJ0WlgzTndYcmp2WURPekNRaExtNHA1MGVUOF9HQk1RUTZfeGFpLXZTa3BnTTZzS1J6YnlqTmVjbXNmR3V4V3B3ZlJHM21BenN2MUY0blhTRTdDRUd5OUNmVWdvQlRyNnA5ZlZXeQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Ships First International Order of LYMPHIR\u2122 to Europe", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQUlIwM0t2WXdRZzMzTzJtbWZtcVd1ekp5dThaY0hqbHhqdi1ETi05Q0ViUE5SbUZLSE9zckpPZmNaZ1VHT2FUc25qb0NUUHp5WE1hOVBSLUNja3VNdU9mMHNtZmVmZGFudzRKMVFITHpqQkhrVW1ReERYcFNVc2xqMlA2aFZPYmU2Rnl6T3dFQ055aTZubG9zTW55QWw1TEV5YzR0N2x2eDVsTHh3RWo3TURTSWEwWjROM2pfNVZKX2wzdw?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTOR Stock Price and Chart \u2014 NASDAQ:CTOR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBfb19pMzljR0tOTlRqWkNrSHpNRUUzS2RLdlFWSEVLeEFkQW1FcUlZZl8yV1FBVUtreW9icUw3ZC1IcEVhNVhWOFdtdk1JUUdnRUY2UG5EWGRzbXNJ?oc=5", "source_name": "TradingView", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR\u2122", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxONDgxU3ZwZTE0VkQtSEQxdFhPTERjZGVhcldVVzl1ZG1yVWhWRUNQT3J5S3NFUmc5SWhlcmtBdkxyeEVla3diaFI0bl9Lcm5QTHhLYThwb0FoRlFCRllxOHdyYi0wZ1o2LUlLaXhBMVZ3ZWczUkRJeFUwcEk0T3FYOG5laWZtMEp3MlozOXprV2t6YzE1Um82cGszNEtlRDFKd0djdmFZQ1ZIZzMzbjlvMXFvWjFHRkw5RFFYRjd2dDV3ZGUyMGxTcFlnbl80QTFHWUFJVFVXSW5mRHVjOUNDaA?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNaG56OFpUWENIb0xBSXFPNDlBaThXQkNYMDRhM0hvSnAtX2R4akhWbDFpbzVra2I3dGtpTldGZGgwN1pua3ZiWXhlY20tUURYdXpQUTN2UWFJckh3SVB5WjRNNXdXM2VPcy1aVlB1blBFZ0o2cEIta1ZDWWlNWHA3RjFYbmREX2JRQXVFamtiR2xYUUdQZjNxUnBNSkVHendEVkx0ckhJRURlM01nQXI5cThNMHZ1Zm9MSEpUT3hzU1A5S09jS1hQeUdEUW9xTzJkTlNQSmlSTlBDczJuRDF4Rw?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAJBVV95cUxPcnFyT1VfWTNhamdiWWktR2lKMWJWOXVucmJSaGMzUFp3ZzZtWDhFaTBvRWczSWY5QWxSX2dSQWJwSXVKdm04SkNVbnlmZDZUdkhEZjNuNl9VNVdyRHU1b01lLW9XWG4tVXpCejNybkRhaHZTc2JHVk1nUjFreFdzdDRhRFNZcFFCZFB6UXI5dFV5RFZfVDhjR2tNSWdwengzMVd1T0NCdXcyMFFKcUVNVk1RclM2RXNRdnpQQ0RsUlY5bWZyREhKQkc5cWJLYWV1MXpEV3Aza1BSaGRLWFNpT3BMaDBuY3lnRGoyR0cxTkluNWJGSElibW01S3Jvbjl2WENrY0plVTBvVlZrbE1rWnZ0UHk0X21kamJvRQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Expands LYMPHIR\u2122 Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxNLTFKQ0JxUUVVNzZJTnVmMTk0RGhCa3hBQ2hwNFlVS0VDUnV2Y0JwU09mOEpwWFFsNW13NFZiUnQ1clk3bHNCTWZJZXJZbV9tSkV4UUc4NzNXR2o1dU5WWVozWGFVM2tyOHAtWERHY21XdmlfLU13TDZabGRpMU1OUVQyZDdHUENidFJhQlFsSHhsRXF6anNILUxPNVhmNTM0MDI0QUpOVFlMNFRFVlFma0RZTjg4RTJ1LU9UaTcwakFVR3F3ZXBScmI2dmdVSWc1TUd2OFA3enkzX3cwSVhWQ1dBd0RFUDZsQkM0dW9zNlFGNkdrdmFwSDBsWVE3eDRwQXJXSm1odw?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQNEhzQm5LcVZJUDNfTmgzUXBrbVktcWUzRXk0ZERKTkNuM0Q0TE01d0JxYzIxR2NvVW1Fd2NlV1RzdFRFWFdXeEZMN24zLVRveDVjZjFWOFlVNWZwc08zZTJKUk5hQW9tMjhTWnJTemtGdllGSjk0eHI5RXNtWEdycy1TdEdyNF8xNGlldmNCZW4xZy04bXhSZFNqeVVIWVVmQUt0VUNhaUFmMlN0UmtkVnFNNlJYbmRoOUgtNW1DY0tjNUJsaUZmQ3Bobnpnajc4bGJxc3FxZTV3VGtpenJjQ2RWUFVEYVNFazV3blUtQnJLLVB6Nk1F?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-10T07:00:00+00:00", "published_display": "10 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (CTOR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5RdGVXTmxSM003X05Tanl5MUJtdjE1dGZuTHpQTkVfQ3BJRmZLVy1uMERYdDdUUjVMS1QzRTEtYkJ0WkxneFlCMGhCVndfMXhVZ19n?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:37:19+00:00", "published_display": "25 Apr 2025 02:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBqUDBleUFtOUFlVlRXX3I4MU53SVdzd2tQaFpONW8zekdaWGxLSHdsamRoUkZmMXZqYWhaY2dBRHFjZ2ZEcW5hMnI1YTJXYm5zT01B?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T22:54:07+00:00", "published_display": "24 Apr 2025 22:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Oncology (CTOR) Stock Price, News & Analysis $CTOR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBmR01DOXBKM3Z3djZNVUt5NnVrNURnd1BEQ3lOUjVPM0VzVWlSeDg4TjFJc2g0bjNOM2FLcThyVmJ6TUFpRW1kQmJJVnBNdUVGY1YtTUc2bklWQQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-08-14T20:37:36+00:00", "published_display": "14 Aug 2024 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAJBVV95cUxPVjFZanlQenJ0ZXJvTU1PRGhxVG1TN0V5UmJ2QjVxQ1ZDM1NtdFVsWFVSb2o4a1hBZUphM0o5eU1Kdnh0SWRCTmVVcWxldmtGMHhHa0tENWV0d1Y3eVZZMTQ2Mk5pSEM3T1I4aVpaMjRjYjVSVjdhUlltVnEwNGpLY1pLVWFxZXVlTGJoZlRhMjlSNGhUeS1tVnEyeG5ENXJ6R3d3azdJaDFfa2VpbUkzbXUtSGZLUm1aV1ExVllNYUZkUHZQVENUSnhSalRId0xteTQ2U3gtR1I5VjR1LWZWTkc0WThBaERyTnJwS21zaXhlYXM2clkxRmV0cjdoaXkyX1VLOUdPVzJydzdnTEVRVU9fMXp6cE81YVRIQmNSbnhjSkVlMFdtRFJtUVlMbG1BdlY0c0JnOFQ?oc=5", "source_name": "PR Newswire", "published_at": "2023-10-24T07:00:00+00:00", "published_display": "24 Oct 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citius Pharmaceuticals (CTXR) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBzUFR4clRxVFVCLWx5SWZWNnRTT2lCUndEZ3JKeWRBd2cwbnFQMVlsZlFJUndnOFdrMlQtZzlBNWdtWVBQVDRmRWM3cUNwQQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-08-03T02:51:15+00:00", "published_display": "03 Aug 2020 02:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 80, "total_relevant": 50, "sentiment_summary": {"positive": 17, "negative": 5, "neutral": 28, "score": 55, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 0.69, "latest_week": "2026-07-10", "one_week_move": 1.6, "four_week_move": 4.1, "twelve_week_move": -21.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.135903, "market_dynamics_buy_signal": false, "relative_strength": -52.793172, "fair_value_gap": -86.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.6137, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.6% over one week, +4.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "PR Newswire", "count": 12}, {"label": "TradingView", "count": 11}, {"label": "TradingKey", "count": 4}, {"label": "ChartMill", "count": 1}, {"label": "Investing.com", "count": 1}, {"label": "Investing.com Nigeria", "count": 1}, {"label": "Finviz", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.6% over one week, +4.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR)"}], "updated_at": "2026-07-16T06:10:18.321841+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}